[
  {
    "ts": null,
    "headline": "Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value",
    "summary": "If you have been watching Gilead Sciences lately, you know it's been a whirlwind, and not in a way that will leave you dizzy, but rather with a sense of real momentum. Maybe you are holding the stock yourself and considering whether to double down, or perhaps you are just circling, wondering if now is finally the time to buy in. Let’s dig in together and see what might be going on beneath the surface. Over the last week, Gilead’s shares climbed 2.7%, which isn’t life-changing in itself, but...",
    "url": "https://finnhub.io/api/news?id=8cb91fa8fc5b89a50d8f9ad574075b9bcc9fddcdc47888ba921d98869f843ea1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761228733,
      "headline": "Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value",
      "id": 137198177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "If you have been watching Gilead Sciences lately, you know it's been a whirlwind, and not in a way that will leave you dizzy, but rather with a sense of real momentum. Maybe you are holding the stock yourself and considering whether to double down, or perhaps you are just circling, wondering if now is finally the time to buy in. Let’s dig in together and see what might be going on beneath the surface. Over the last week, Gilead’s shares climbed 2.7%, which isn’t life-changing in itself, but...",
      "url": "https://finnhub.io/api/news?id=8cb91fa8fc5b89a50d8f9ad574075b9bcc9fddcdc47888ba921d98869f843ea1"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?",
    "summary": "Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=a251865bc23c9d1dbd22438516e05c46407518ec52994a6a65f4afc8990b23b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761228006,
      "headline": "Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?",
      "id": 137198178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=a251865bc23c9d1dbd22438516e05c46407518ec52994a6a65f4afc8990b23b7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta",
    "summary": "FOSTER CITY, Calif., October 23, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across PBC and viral hepatitis will include late-breaking data and three oral presentations.",
    "url": "https://finnhub.io/api/news?id=e7ffcdb058e0e815798e8ea594a5d151de5a7ecbed1394a5afa719d82fb8f8a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761220800,
      "headline": "Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta",
      "id": 137198179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., October 23, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across PBC and viral hepatitis will include late-breaking data and three oral presentations.",
      "url": "https://finnhub.io/api/news?id=e7ffcdb058e0e815798e8ea594a5d151de5a7ecbed1394a5afa719d82fb8f8a1"
    }
  }
]